Selective inhibition of the NaV1.8 voltage-gated sodium channel has been a topic of interest in pain management. The study delves into the efficacy and safety of VX-548, a selective inhibitor of NaV1.8, in managing acute pain post-surgery.
- Investigated the selectivity of VX-548 for NaV1.8 inhibition in vitro.
- Two phase 2 trials conducted: one post-abdominoplasty and the other post-bunionectomy.
- Abdominoplasty trial: 303 participants, four treatment groups (high-dose VX-548, middle-dose VX-548, hydrocodone bitartrate–acetaminophen, and placebo).
- Bunionectomy trial: 274 participants, five treatment groups (high-dose, middle-dose, low-dose VX-548, hydrocodone bitartrate–acetaminophen, and placebo).
- Primary end point: time-weighted sum of the pain-intensity difference (SPID48) over 48 hours.
- High-dose VX-548 showed a significant difference in SPID48 compared to placebo: 37.8 (95% CI, 9.2 to 66.4) post-abdominoplasty and 36.8 (95% CI, 4.6 to 69.0) post-bunionectomy.
- Lower doses of VX-548 yielded results comparable to placebo.
- Common adverse events: headache and constipation.
- High-dose VX-548 effectively reduced acute pain over 48 hours post-abdominoplasty or bunionectomy compared to placebo.
- Adverse events linked to VX-548 were mild to moderate.
Did You Know?
The NaV1.8 voltage-gated sodium channel plays a crucial role in transmitting nociceptive signals, which are central to pain perception.